Wall Street Firm New York Global Securities Issues Updated Research Coverage for Bodisen Biotech
Tuesday June 21, 8:58 pm ET

NEW YORK--(BUSINESS WIRE)--June 21, 2005--Bodisen Biotech, Inc., (OTCBB: BBOI, website: (/) announced today that New York Global Securities, a Wall Street investment banking and research firm has provided updated research coverage for the company.

The analyst providing the updated research coverage has extensive knowledge and experience of the U.S. and Chinese markets. The full research report is available at the following sources: Bloomberg, Zacks, Thompson/First Call as well as Bodisen Biotech's own website (/).

New York Global Securities, Inc. (http://www.newyorkglobal.com) is a U.S. based investment banking and brokerage firm which specializes in middle-market and emerging growth companies. NYGS is a member of the NASD and is headquartered in New York with an associated office in Beijing, China.

Utilizing proprietary technologies, Bodisen sells over 60 packaged products in 3 product categories: Organic Compound Fertilizer; Organic Liquid Fertilizer; and Pesticides & Insecticides. Bodisen's organic fertilizers can be absorbed by plants within 48 hours while enriching soil conditions without the damaging effects associated with chemical fertilizers.

About Bodisen Biotech, Inc.

Bodisen is headquartered in Shaanxi, China, an agricultural hub of China and the economic gateway to the western regions of China. The Bodisen brand is a highly respected organic brand in China. Its "green" products support the mandate of the Chinese national government to increase crop yields for the purpose of decreasing China's dependency on food imports.

Safe Harbor Statement

This press release may contain forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These statements are based on the current expectations or beliefs of Bodisen Biotech, Inc. management and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements.

Bodisen Biotech, Inc.
Investor Relations, 212-566-3503
info@bodisen.com

Source: Bodisen Biotech, Inc.